The Calmer Co International Limited (CCO) Earnings Call Transcript & Summary

May 7, 2026

Australian Securities Exchange AU Consumer Staples Personal Care Products earnings 50 min

Earnings Call Speaker Segments

Zane Yoshida

executive
#1

<<inaudible>> The Calmer Co's Q3 FY '26 results came out this morning. I'm the Founder and CEO of the Calmer Co, and Matthew Cowell, our Chief Commercial Officer, is with us as well. What really sets the tone for today's discussion is that this was a quarter of transition for CCO — revenue held steady, but the quality of that revenue improved. Thanks, Matt. Let's go to Slide 2, please. We'll work through 3 — sorry, 6 key areas on our agenda today. Those include the strategic pillars, which are the company's 4 growth engines. We'll cover the quarterly highlights, the headline numbers and the stories behind them. We'll discuss revenue performance broken down by geography, channel and product format. Then we'll move to an exciting area of transition, quarterly revenue as well, and the momentum that's building in the wholesale and B2B channel under strategic pillar 4 of the business. We'll talk about cash costs, the balance sheet, working capital and discipline, of course, under that agenda item, and we'll also look at the broad regulatory progress in the Calmer industry in the United States, here in Australia, and regionally across the Pacific — important category tailwinds and certainly priorities for the Calmer Co given how involved we are in shaping some of the thinking, strategy-wise, on those next steps.

Zane Yoshida

executive
#2

Thanks, Matt. So, as we've said over the past several quarters, those 4 pillars are the main things driving the Calmer Co and where our attention sits. During the most recent quarter, we took some pretty significant steps when it comes to sourcing regionally, manufacturing excellence, and our capacity to innovate at the Calmer Co. The last time we spoke, around the Q2 FY '26 results, we confirmed that PNG had been added beyond our regional sourcing alongside the Fiji supply chain. Over the past quarter, we've also managed to lock in supply from Vanuatu. We got to go to Vanuatu, sit down with key exporters, and that included meetings with governments held in Port Villa in March, and I'm pleased to report that we've since progressed to securing supply of high-quality Noble Kava straight out of Vanuatu, coming into Australia but also heading into Fiji for processing and export to back the Pacific regional strategy we have internally and to build specifically on the Tui May brand. Someone's asking, is the webinar still running? Are we live? Yes. We're live. Let me just sort this out — I've just had a message from somebody registered for the webinar asking whether we're still holding the webinar today.

Zane Yoshida

executive
#3

I trust that our signal is coming through clearly and strongly.

Matthew Kowal

executive
#4

Yeah, I can spot — sorry, it's 13 people who've joined the room, not 3.

Zane Yoshida

executive
#5

The main thing to call out on regional sourcing is that Vanuatu is now part of ingredient supply for the Takuma brand, and more strategically for our extract formats, as I mentioned earlier. We're definitely making a lot of headway on relationships there, which feed into Fiji and also into strategic spots here in Australia for value add on the extract side of the business. Our second strategic pillar is direct-to-consumer, Amazon included. E-commerce was roughly 36% of revenue. Amazon accounted for $497,000 of that, and that comes alongside a choice to cut advertising and marketing spend for D2C specifically by 30%, which is a more targeted approach to our direct-to-consumer channel. The third strategic pillar is profitable and scalable retail. We're keeping up positive momentum in retail relationships with Kohl's and Woolworths, having finished range reviews this quarter. The 50-gram and 150-gram pack sizes we sell with Kohl's are still #1 and #3, respectively, in the stress subcategory. And with some positive momentum, we're dipping our toes in the water, so to speak, on next steps in the U.S. when it comes to potential retail partnerships.

Zane Yoshida

executive
#6

The company's fourth strategic pillar centers on bulk ingredients, and we're glad to share the positive momentum and quarter-to-quarter growth: a 78% quarter-on-quarter rise to 646,000 in revenue contribution from the wholesale channel, 33% of our revenue mix now across Karako, plus strong repeat ordering from IMCD and U.S. beverage customers. Thank you, Matt. The key highlights were that we closed the quarter with $1.6 million in revenue, broadly in line with Q2. That said, the shift toward higher-quality channels — something we've focused on strategically and previously communicated to our investors and stakeholders — was building momentum around our wholesale channel. We finished the quarter with record March sales of $1.2 million. And as I said, the tremendous transition this quarter was a 78% increase in wholesale growth quarter-on-quarter, with wholesale now contributing 33% of total group sales. Also, given the positive momentum into the U.S.A., the U.S.A. share of revenue now goes past Australia. I think we were circa 45% U.S.A. revenue mix in Q2 FY '26. The U.S.A. split of revenue now stands at 59% for the quarter. The underlying mix of the business continues to strengthen, of course.

Zane Yoshida

executive
#7

During the quarter, we completed a capital raise of $1.6 million, and at quarter end we reported $1.5 million in cash. We're strategically continuing to build inventory to feed the pipeline of growing revenue through our wholesale partnerships, and momentum is also building across direct-to-consumer as well as retail as we take our next steps. Cost discipline stays a key focus as we keep a close eye on our breakeven position, and marketing spend, as I mentioned earlier, was down 30% quarter-on-quarter, while staff costs for the quarter fell another 5.5%. Thank you, Matt.

Matthew Kowal

executive
#8

Thanks, Zane. Moving on now to revenue. There's a key point Zane brought up on the previous slide that I want to highlight. Revenue held steady, yet there was a genuinely significant overall change in the mix, and I want to discuss where that change originates — namely, our channel focus. One of the main ones, wholesale, rose sharply, but what probably matters most is grasping that repeat or recurring cycle and having the ability now to truly fine-tune it and scale it going forward. That really showcases much of the investment into, I suppose, this appealing margin channel for us ahead. U.S. Amazon continues to be a key anchor for the online business and clearly offers even more growth for the U.S. market as well. And retail, though temporarily softer following the festive holiday season and some effects related to new planograms, is still very steady. And most importantly, as I mentioned, it keeps up that strong ranking as a truly leading Kava product, and also as the leading first and third ranking product in the Coles stress category. The last part was simply an overall note about that mix in the shift, or split, across channels, with an understanding of the heavier weighting now toward higher net margin channels like wholesale.

Matthew Kowal

executive
#9

Once more, the chance we see in America stays squarely where our attention is. And clearly, revenue is beginning to track that division now — the positive side, just to explain why we take that approach, is that AU is still strongly placed, as I noted regarding our retail positions as distribution grows and e-commerce routes expand in that market too. So it keeps showing itself to be a solid, workable growth market. Crucially, Fiji will keep contributing in that same way, with the authenticity and provenance narrative that truly underpins our whole business. Yet the major chance sits in the American market, with a sizable ingredients prospect in nutraceuticals plus a branded segment expanding fast, including the surge in ready-to-drink and stick packs. And clearly, our chance through developing our own extracts, really aiming to seize an opening there to keep building that. On the strength of that, we put money in during the last quarter with some presence at Expo West, the biggest natural food and beverage expo globally, to keep pursuing the openings across every one of those channels — wholesale, retail and online. Speaking to that move toward a more balanced mix, you can more or less observe that we have a fairly even split across the 3.

Matthew Kowal

executive
#10

A significant portion of that stems from our push to grow wholesale. Naturally, the momentum we've discussed regarding that net margin—appealing and high—matters greatly here. I believe we've managed to keep retail performing well. As I mentioned, speaking to that powerful profitability effort, collaborating with Kohl's and recognizing both the additional domestic growth and the international distribution that hasn't launched yet. Beneath all that sits our reliable, established e-commerce channel over the long haul. Zane mentioned that we've cut back on marketing investment since we've concentrated hard on targeting and making certain our marketing messaging is perfectly dialed in as we prepare to expand it across the coming 2 months. A crucial piece I'd like to devote some time to on these next 2 slides, and also pull Zane into the conversation a bit regarding product mix, is grasping the chance wholesale offers plus certain major markets where groundwork has already begun. To start, we have a tremendous opening in a mix of high revenue and high margin, and knowing the range from bulk powders all the way to the CO2 extracts provides us room to propel the business and that channel considerably.

Matthew Kowal

executive
#11

Over the past two quarters, we've had several meaningful repeat-order cycles with key partners. Building on those, along with the pipeline as a whole, gives us a strong chance to spread that wholesale growth across the entire quarter and really sets the direction for where we want to take the business in the quarters ahead. And obviously, that in itself supports predictable revenue and lets us plan more effectively and hold and grow those attractive margins as we scale. An important piece of this — we've discussed our splits a lot previously, and traditionally we've remained heavily weighted toward carver powder, with some of our own RTD and medicinal formats emerging. But this quarter really begins to reveal a clear-cut opportunity in extracts and, effectively, that wholesale ingredients market we're heavily focused on. There are a few key real benefits here. First, it expands our reach, letting us really focus on everything from the nutraceutical channel as a supplier to brands and companies, through to a growing market in the U.S. that I mentioned earlier, and actual consumer brands too, using this ingredient format.

Matthew Kowal

executive
#12

That larger amount for each kilogram really gives our B2B ingredients platform a solid foundation—the one we've established and intend to use to push that margin going forward. Zane, you were wanting to address a few points here, along with some of the developments on our radar?

Zane Yoshida

executive
#13

Right, so if we circle back to strategic pillar 1 and innovation — that capability is part of our continued success and a critical success factor as we move into the extract channel — we had already announced the launch of our 65% extracts in paste form. We'd also announced the launch of our 30% standardized carbo lactone powders with different excipients. The next pipeline innovation we've been focused on for the last 2, 3 months is addressing water solubility, in both a liquid format and a powder format, since that's an important next step, especially when it comes to converting more beverage customers and bringing them alongside the strategic partnership we announced in March around the wholesale channel and the large first beverage functional beverage company, Matt. So bringing in #2, #3, #4, #5 based on the various conversations we keep having out of the U.S.A. is the importance of water solubility. So we've adopted a dual-pronged approach here to make sure we're addressing a water-soluble powder, but also a liquid format we can move forward with these customers and these relationships. So just coming back to Slide 10 on capital and costs.

Zane Yoshida

executive
#14

We ended the quarter with $1.5 million of cash on hand — the main point of this slide is really about staying disciplined while we scale. We finished up with a $1.6 million capital raise, which strengthened the balance sheet over the course of the quarter. And naturally, we've been building inventory very strategically to make sure we keep supplying the wholesale side, that tremendous wholesale channel, and the growth we're seeing there, since it's a higher-margin channel that's been a major focus amid the transition this quarter. That's now showing through very clearly, with revenue split across direct-to-consumer, including Amazon, retail, and now wholesale at roughly 33% each, all contributing to top-line revenue for the Calmer company. Cash receipts from our customers came to $1.63 million for the quarter. And of course, cost discipline, as I mentioned earlier, stays a big priority — we cut advertising and marketing spend by 30%, taking a more targeted approach to how we deploy capital there. Staff costs, again, were reduced by a further 5.5% this quarter, now at roughly $312,000, after a 4% reduction in the prior quarter. So the key message is that growth funding is in place.

Zane Yoshida

executive
#15

We're putting working capital to work with a genuine aim of building up inventory to supply the expanding engines throughout the strategic pillars we've outlined to you before. Thanks, Matt. I believe this is a really significant one as we think about our upcoming moves into the U.S.A. and further afield. I've put this slide in on the regulatory framework and how it's progressing, not only in Australia but also in the United States, and on establishing the basis for scale, which matters greatly across the Pacific. So returning to strategic pillar 1 and making sure we have the proper quality framework in place, we have the right regulations in place from the Pacific, given the talks held by Pacific heads of government in 2024 in Tonga. The Pacific Island Forum Secretariat facilitated this, and the heads of government agreed to a regional approach through a regional KAVA development strategy. That is now well underway, with the heads of government committed to harmonizing the cultivation of Noble KAVA, the processing that follows, and export so as to meet international standards. So beginning with Australia, for example. Standards Australia has announced that a technical committee has been formed here in Australia, along with the development of a regional standard for KAVA.

Zane Yoshida

executive
#16

And we should also think more broadly, past Kava mixed with water in its traditional formats, to bring in Kava extract as well. So this is significant news for the industry and positive news for the Calmer Co, given our strategic direction to move beyond traditional Carver powders, while also concentrating on the building momentum we've observed across our wholesale channel and especially the extract formats we're bringing to market, with confidence from repeat orders arriving from various customers. So right now, just to give everyone some background on the regulatory environment here in Australia: tablet and capsule formats are still regulated by the TGA as a complementary medicine, while the powders we sell in Kohl's and Woolworths, for instance, are currently still regulated by Fazan's, Food Standards Australia and New Zealand, as a food. However, lobbying with governments continues to ensure we get a finalization of the commercial import trial and final regulation as a food. So we don't have to bring Kava in via the Office of Drug Control, given we've had good success at retail. And as Matt mentioned, #1 and #3 in the stress category Australia-wide.

Zane Yoshida

executive
#17

Internal surveys show it isn't only Pacific Diaspora members who drink our Kava — Pacific Islanders make up 4% of our customer base. So Aussies are now consuming Kava on a daily basis. And a lot of clinical trial evidence supports KAVA's benefits as an effective anxiety treatment historically, including with the water extracts we sell here in Australia — Aussies are sleeping better and feeling less stressed. And certainly, with the momentum and the shift toward less alcohol consumption among Gen Zs, it's filling a nice niche in that regard too. So good strong progress when it comes to the Pacific regional strategy and the developments with the regional KAVA standards in that regard with Standard Australia. In the United States, we've seen the FDA previously communicate on recognizing KAVA when mixed with water as a single ingredient as a food. In March, the state of California moved to also recognize the same. This follows Hawaii and also the state of Minnesota from memory. So again, positive momentum in the U.S.A. with recognizing KAVA as a food when mixed with water. So more broadly with that background, I guess, is really the framework that's currently in place with Codex Elementaries.

Zane Yoshida

executive
#18

And for some background, Codex Elementaries is made up of the World Health Organization and the Food and Agricultural Organization, and it provides oversight from a standards perspective for food and beverages around the world. So that work has been in place since 2017, and given the influx of different KAVA formats in the U.S.A. and Australia, it is building or rebuilding confidence and trust with KAVA. And we can see that now with the momentum in the U.S.A., with the momentum in Australia, with various bodies supporting standardization and, again, supporting the regional KAVA development strategy already in place throughout the Pacific. Internationally, there continues to be a lot of work around lobbying for market access through the Pacific Island Forum Secretariat and various subcommittees that are working on a geographical indication to protect KAVA as an ingredient unique to the South Pacific or unique to the Pacific, but also various meetings that have been held with the United Kingdom, in particular, to consider a pilot trial similar to what's already in place here in Australia. So with the confidence that is building through the regulatory work that's in place already, but also positive momentum in Fiji, for instance, with the completion of the KAVA consultation for the KAVA bill, which will likely be heard by parliament in the next 2 to 3 months for parliamentary review before final adoption and the establishment of a Fiji KAVA Council in the country to look to regulate the industry and ensuring that this aligns with the good work that PIFs continue to do with the regional KAVA development strategies, ensuring that the traceability, the quality of Kava that's being exported out of Fiji continues to remain a regional leader in that sense, together with the considerations around the harmonization thereof across the Pacific.

Zane Yoshida

executive
#19

It's an exciting period on the supply side and from a quality framework standpoint, and also when it comes to the regulations that back that positive momentum and the next steps to make sure that, beyond Australia and beyond the United States, we at last secure market access into the United Kingdom and possibly into EU markets as well. This ensures a more enabling environment across Australia, the U.S. and internationally when it comes to broadening distribution points for KAVA and Kava-derived ingredients, which directly supports our retail, wholesale and B2B extract strategies. Thank you, Matt. So we are definitely heading into Q4 with momentum and a clear plan, given the transition in Q3 FY '26. And the strategic priorities for the team are very clear. It's continuing to scale wholesale and B2B momentum, converting the inventory we built throughout the quarter into revenue across powder and CO2 extract formats, and deepening U.S. distribution. We've touched on -- or Matt touched on earlier our visit to the U.S. earlier this year at the largest retail show in the U.S. with Expo West and some of the discussions that we had at that time. And certainly, we're looking to consider how we dip our toes into the water as it relates to U.S. retail expansion.

Zane Yoshida

executive
#20

Pushing operating leverage and making sure marketing and staff management expenses stay under control as we keep scaling — that's a big priority, along with cost discipline in Q4. And moving toward breakeven and cash flow breakeven is, as that transition quarter showed, positive momentum that's building into wholesale and higher-margin channels with the extract formats we're launching or launched in earlier quarters. So really, as I mentioned, it's a pivotal quarter for us as a company. Revenue is broadly stable, but it hides a significant underlying shift toward higher-quality revenue streams. We saw that with a great 78% quarter-on-quarter increase in our U.S. wholesale and B2B product formats. And we had a record month of $1.2 million in revenue for March, which is a key indicator of the growing scale and repeatability of our wholesale order cycle; with a strengthening balance sheet, disciplined cost management, and inventory positioned to support growing demand, we're certainly well placed to execute into Q4 and beyond. Driving revenue through higher-margin channels is a key focus for the team as we move toward sustainable cash flow breakeven. Thank you, Matt.

Zane Yoshida

executive
#21

So, we’re checking whether any questions have come in. Could someone give us a sense of what April ’26 revenue came in at, please? Did the momentum from March continue, or are we still waiting to see that? On this webinar, we can’t comment on April revenue. But as we’ve done before, we’ll certainly keep updating stakeholders on our quarterly progress and the momentum on that front. I think there are no other questions besides that, Matt. If there are particular talking points, though, I believe it’s really about wholesale and, naturally, the next steps into the U.S.A. So perhaps you could give us some insight from your desk into what that opportunity looks like, and let’s spend the next few minutes discussing the U.S.A. I’m certainly happy to start that off, given the...

Matthew Kowal

executive
#22

A few questions have come in through the chat.

Zane Yoshida

executive
#23

What's my view on that? No, Matt, I'm not seeing anything at all.

Matthew Kowal

executive
#24

All right. Tristan has sent one in. Could we get some visibility into the route toward breakeven profitability across the whole company? When might a quarter turn positive? Zane, do you want to take a crack at that, and then I can run through these quickly — I'll pass them along.

Zane Yoshida

executive
#25

Absolutely, yes. As the shift we made this quarter shows, along with where we're heading strategically across our pillars, creating momentum in wholesale and in higher-margin channels is still a priority. We've shown that across the past 2 or 3 quarters. We're making sure our attention stays on driving momentum and revenue in the wholesale side, since that part delivers the biggest net cash contribution to the company's overall cash flow, and that focus will carry on, as I said in my summary going into Q4. I'll also briefly address this.

Matthew Kowal

executive
#26

What's the timeline for Cabo Pena Colada drinks becoming available for purchase in Australia?

Zane Yoshida

executive
#27

I suppose that really ties back to the range review, and we have finished that with Coles. For this one, we are certainly taking a two-part approach. Here in Australia, Matt, we intend to sell it as a complementary medicine; we have completed all the TGA submissions and the entire Australian register for therapeutic goods process. Right now we are awaiting some positive news from goals so that, with the initial launch volumes, we can move this through both the direct-to-consumer channel and our retail channels, since that raises the MOQs and lowers our cost with these new product formats that we introduce to market.

Matthew Kowal

executive
#28

Then there are a couple of other questions along the same lines, I think, all circling the same point—sort of asking about the roughly $1.2 million in revenue in March and, I suppose, the capacity to grow that into revenue you can count on month after month, and, I guess, around how the lumpy wholesale revenue pieces factor in. Not sure whether you'd like to speak to that, or I can add a few details myself.

Zane Yoshida

executive
#29

Sure. Please proceed.

Matthew Kowal

executive
#30

Yes. Look, as the question itself basically points out, this shows how wholesale build-up tends to be cyclical right now — lumpy. What it does demonstrate is the potential, with the pipeline growing month after month, for that to turn into a repeatable month. A lot of it, quite clearly, comes down to having time to build up our extracts and our wholesale business overall, plus the total customer count, so that this can be spread across the months. The other factors feeding into it are, obviously, the opportunity and what we're seeing as we build both retail and online, both here in Australia and the U.S., which will clearly contribute to that. I think that's the last of the ones that have come through chat.

Zane Yoshida

executive
#31

Let me perhaps start with a few questions about the U.S.A. and what comes next, Matt — given how excited everyone is internally and the effort to repeat the success we've enjoyed here in retail. Across Australia we hold the #1 and #3 positions with coal supermarkets. At Expo last quarter we had some productive meetings. When it comes to retail in the U.S.A., we're cautious about its sheer size, the commitments that go along with that, and how those decisions would affect cash flow. So for the Calmer Co, what might potential next steps look like when considering a retail footprint and replicating the success we've achieved here in the U.S.?

Matthew Kowal

executive
#32

Yeah. So I think a few key factors are at play here. Probably the biggest one is simply having a genuine grasp of that value chain and every component within it, since we also have to factor in the timing cycles for those pieces — when payments come in, when we'd be holding inventory, and how that gets carried out at store level. So there's a certain amount of planning that will really spell out anything from a single major retail partner, and that then scales up the further you proceed and the more you grow. So that takes a bit of time. What matters most there is that we're pursuing this alongside some key commercial partners. So we're getting the understanding from what we'd traditionally term brokerage folks who can assist us in executing on the ground, provide us with full visibility, and leverage their relationships to give us insight into every market, every retailer, and the areas where we see a viable white space for what we're doing. So in brief, some planning is involved over the coming quarter.

Matthew Kowal

executive
#33

After that, execution really hinges on deciding who we prioritize first, what that requires from a supply chain standpoint, and then making sure throughout that stretch — and I think we coined the phrase inch-wide mile deep — that we do everything right with a limited number of customers. That way, when the moment to scale arrives, we can go full throttle. The market's size, as you can imagine, even from a retail perspective, a typical national retailer runs anywhere from 500 to 2,500 stores. And as I mentioned, we're discussing close to 100 major retailers that we could potentially target across the market. So there's some prework we need to confirm is in place. And then we have to ensure that in those first steps into the market we learn everything necessary to be able to go full throttle when the opportunity presents itself. And it may sound like a great deal of planning. A lot of this can be accomplished quickly with the right partners, but it matters that we tackle each of these points before diving in, since it could eat up a lot of cash flow.

Matthew Kowal

executive
#34

That means we have to invest at the right level.

Zane Yoshida

executive
#35

Yeah. And after visiting quite a few stores with you last quarter, Matt, we're seeing plenty of opportunity. But then again, I believe there's considerable opportunity in white label too. So did you want to say a few words about that as well?

Matthew Kowal

executive
#36

Yeah. So, from the individual feedback we got during our store visits, what we found was substantial expansion in the ready-to-drink ITD segment for Kava. And that's likely true beyond just Kava — you're seeing a surge in natural functional ingredients across the U.S., with the major player and the mushroom varieties really widening that category at retail. Alongside that sit some of the more traditional medicinal products. But another major area you can benchmark against is a very sizable pouch ingredients cycle that's taking hold. So whether it's single sticks that consumers pick up at the counter to add to their water bottles, or bigger pouches processed at home, driven by brands such as A1, where people are really leaning into that consistent intake of a core functional ingredient in their diet. All of this sits alongside the steady, natural rise in Kava awareness. And as we mentioned earlier, last year's study showing about 10.7% of American adults had tried Kava within the prior 12 months is very much beginning to show up in what we observe on the retail floor, heading into roughly the equal 1, #2 position in the natural space there at Sprouts.

Matthew Kowal

executive
#37

You had roughly 4 to 5 distinct Kava items — a couple of them in RTD, and a couple sitting in that traditional medicinal category. So the chance is definitely out there. It's somewhat more dialed in on where it ought to be. And then the second piece, which Zane mentioned, is that major brands — be it Whole Foods or Sprouts within that natural channel — have already begun building out their own branded offerings in this area. So natural interest keeps building, which gives us a natural opening to come in and leverage our edge in supply chain and sourcing.

Zane Yoshida

executive
#38

Then the second item is wholesale momentum, Matt. Beyond extracts, we're aware that we've achieved solid results during the past few quarters, with extract growth and repeat ordering cycles coming through. At present there are 600 Kava Bars and more across the United States. So perhaps we could briefly address that—some of our plans and some of the actions we're already taking to sell material into the Kava Bar channel, Matt, since from what we're seeing that is certainly growing. So perhaps, for everyone's benefit, just cover that a little too, please.

Matthew Kowal

executive
#39

Absolutely, absolutely. Also, before I forget, another question has come in that you can probably tackle right after this. It's simply: do you have a plan in case the June options get converted? So, I'm not certain whether that's something you want to address. But regarding that Kava Bar—or, I suppose, the on-premise opportunity—the numbers at Kava Bar keep rising, along with overall interest in that space. As a result, a direct opportunity exists. They rely heavily on bulk powder formats as their core, with some standardized extracts added on top. We've already begun figuring out how to supply them directly, but also—given how fragmented this industry, or channel, is—the real strength will come from partnering with distributors who visit these bars weekly, if not daily. And we're already a couple of significant steps along in partnering with one of them, which should let us open up that space more effectively, with some hopes, as I said, of officially kicking that off in the near future.

Zane Yoshida

executive
#40

Absolutely, and it's an exciting space. I keep up with a lot of Kava forums and KAVA conversations on social media, and it's definitely a very lively and very varied community. And after visiting Kava Bars myself back in 2023, I can tell you they range from your 5-star Kava Bars all the way to your style Kava bars in the mix. But what we're seeing is growing demand. And based on the survey the KAVA Coalition ran late last year, where U.S. consumers have tried KAVA more than once in the last 12 months, I believe around 56% of those people had tried KAVA at a physical Kava Bar. So it certainly has a role in building awareness and sustained momentum that drives trial and then conversion and repeat customers. 30% of those were buying products online. So it definitely plays a very important part in building continued awareness of the positive benefits of KAVA. Some of the, I suppose, difficulties for those KAVA bars involve trying to sell other ingredients alongside Kava, which creates some mixed messaging in the market, particularly from regulators, and that refers to Cat Kraton specifically, Matt, which is the only concern I have there.

Matthew Kowal

executive
#41

Yes. No, I believe the heightened scrutiny and tighter rules around Com and even CBD formats are themselves helping fuel some of that wider interest — from KAVA bars, but also more broadly across online sales and products that can obviously come from KAVA, which, as you mentioned earlier, is progressing with every constructive step when it comes to regulation and the way it's evaluated as a product.

Zane Yoshida

executive
#42

Yes, absolutely. And I suppose, considering KAVA has enjoyed past success in certain of these major markets, yet also encountered some difficulties in earlier times, and with backing now coming internationally through Codex Eamentariious, the regional development plan for KAVA and that framework being established at present — significant bodies such as Standards Australia stepping in to work toward setting KAVA standards that go past kava powder combined with water and could potentially cover extracts — these are meaningful next steps toward restoring trust in kava and KAVA formats re-entering the U.S.A. It's really crucial that we have the proper foundations for scaling with the opportunities that lie ahead, and also to unlock additional market entry into the U.K. and the EU too, which I know is definitely well underway judging by certain parliamentary discussions held in Suva last week inquiring precisely where we might be headed regarding potential U.K. market access. So there could be some encouraging developments coming our way on that front. And what excites me is, given your deep experience in the U.K., Matt, and how swiftly we might potentially activate some of those connections once we arrive at that point, which is a significant one.

Matthew Kowal

executive
#43

Absolutely. Actually, I'm looking forward to that.

Zane Yoshida

executive
#44

Yes. So, regarding the question about how we would use the funds: if we were to see a positive conversion of the options at the end of June, our main focus really is vertical integration. Right now, with the wholesale relationships, particularly in the extract formats, a great deal of that manufacturing is outsourced, and we give up margin because of it. So as we establish more relationships and gain more momentum on that front, I can say confidently that we would look at potentially producing those formats domestically, or working strategically with partners in the country, to make sure we achieve true vertical integration in our manufacturing capability and capture that margin through that process — while also taking into account paying down debt with those next steps under the plan. And Matt, potentially accelerating our dipping of our toes in the water, so to speak, with Retail U.S.A.

Matthew Kowal

executive
#45

Sure, I can do that.

Zane Yoshida

executive
#46

All right. Does anyone else have a question coming in?

Matthew Kowal

executive
#47

Not right now, no. From what the chart shows, that seems to be the bulk of it.

Zane Yoshida

executive
#48

And then there are the other items I think matter. We have discussed the regulatory side and how that is moving forward. We have discussed retail, including what we think about retail in the U.S.A. Once again, direct-to-consumer is heavily centered on spending on marketing ads so that we secure the proper conversion. Momentum at Amazon USA remains favorable. And I would say I am also glad to see platforms such as Amazon now seeking to verify the quality of the KAVA sold through them. So I believe, with our business focus on making sure from the outset that we had the right manufacturing methods and accreditation in place with the FDA, the fact that we have been audited and are registered with the FDA for dietary supplement compliance, and the fact that we are now in our 13th year of food safety orders with HAA Australia, this gives us a solid edge on that front too. So we will see, thanks to the strong work Andy keeps doing and the market share we hold on Amazon USA, now at circa 10% split between Taki Mai and the Fiji KAVA brands, that we keep gaining a firmer foothold as some of those competitors may fall away in due course because of these tougher requirements arriving through sales platforms like Amazon USA.

Matthew Kowal

executive
#49

Sure. What I’d say is that we keep concentrating on making our supply chain stronger, and clearly on expanding the pipeline feeding into wholesale, which is simply giving us a really solid base from which to grow. Yet, as you pointed out, the key piece is that we also need to add to that through the online and retail chances for our own products or white label product—that part is enormous.

Zane Yoshida

executive
#50

Yeah. So with the summary we just walked our friends on the webinar through, I'd call it an execution quarter. Thanks so much for spending the time with us. That's all the questions we have. <<inaudible>> and we'll see you next quarter.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete The Calmer Co International Limited transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to The Calmer Co International Limited earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in The Calmer Co International Limited or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.